Abstract No : 1017
Abstract Type : Poster Discussion Session
Indication : Triple Negative Breast Cancer
Intervention : bicalutamide + palbociclib
Company : Pfizer
Technology : Small Molecule
As of 1.1.20 33 pts were enrolled on study with median (med) age 67 (42-79), performance status 0 (0-1). Number of pts with visceral metastases: 20, measurable disease: 22. AR% 1-9: 3, 10-50: 6; 51-100: 24. Med prior lines for MBC: 3 (0-9). Best response: (31 evaluable pts): 11 pts PF at 6mo: 10 SD . 6mo, 1 PR. Med wks on study: 14 (2-101). Toxicity . 10% grade .3 related: Number of pts with leukopenia: 21, neutropenia: 21, lymphocytopenia: 6, thrombocytopenia: 3. One pt with febrile neutropenia. One death due to disease progression within 30 days off study
In this selected subset of pts with AR+ TN MBC, this study met its prespecified endpoint with 11 pts PF at 6 mo on B 150 mg + P 125 mg. B+P has been well tolerated with no unexpected toxicity observed.
Finally there is some development in AR+ metastatic Triple Negative Breast Cancer as bicalutamide + palbociclib has shown activity in these patient sub group with high unmet need. Further studies are needed to develop predictive biomarker.